Generalizability of clinical trial results for generalized anxiety disorder to community samples.
about
Pharmacotherapy for anxiety and comorbid alcohol use disordersProfile of agomelatine and its potential in the treatment of generalized anxiety disorderQuality and quantity of information in summary basis of decision documents issued by health CanadaToward National Estimates of Effectiveness of Treatment for Substance UsePrevalence of subthreshold hypomania and impact on internal validity of RCTs for major depressive disorder: results from a national epidemiological sample.Generalizability of pharmacological and psychotherapy clinical trial results for borderline personality disorder to community samplesThe National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findingsPost-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan.A trans-diagnostic review of anxiety disorder comorbidity and the impact of multiple exclusion criteria on studying clinical outcomes in anxiety disorders.Novel routes to bipolar disorder drug discovery.Advancing psychotherapy and evidence-based psychological interventions.Estimation of Population Average Treatment Effects in the FIRST Trial: Application of a Propensity Score-Based Stratification Approach.Generalizability of findings from randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network.Generalizability of Clinical Trial Results for Adolescent Major Depressive Disorder.Comparing pharmacological treatments for cocaine dependence: Incorporation of methods for enhancing generalizability in meta-analytic studies.Trial participant representativeness compared to ordinary service users in a work rehabilitation setting.
P2860
Q24186575-118C37BB-5352-42ED-AADE-6D4B8A443EDFQ26864049-922449D5-93A1-4983-94F7-3F1DFCB1BB97Q28541228-55DBE400-DE78-4124-9149-80E5A20EC42AQ33852341-2F459038-EE57-4912-A6DD-C409F160BB83Q34584230-27332B0A-9165-4EFB-A471-32F412396DB5Q35214927-155523A9-57DA-479F-902E-B09A208484A6Q36200016-3A50E36B-06C8-40BB-A0A8-1AC65DD43A33Q36942805-99561429-917E-41AD-AF5A-4BAFC5BF2990Q37061869-045AF1D7-868F-4CA6-8900-CCEDD8E74142Q38109244-995FB53C-B2A4-4159-8A5D-7896D4D768E2Q38174533-AC7D6515-68A2-4B01-8B8E-18E5FD381659Q38612362-F2B26F9E-AE9B-429B-AE6A-C8A8D71654D3Q40338637-8ABE50C6-A48B-4234-B5D9-AE4DF9E66B8CQ47582630-2E8BD471-6527-49DD-94A2-30CBC50E3232Q49719710-0AE25F69-10D0-43D8-90C3-1B87951DE6A5Q55292903-AF1000CC-6F73-45DD-B110-410FD4E6C5A0
P2860
Generalizability of clinical trial results for generalized anxiety disorder to community samples.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Generalizability of clinical t ...... disorder to community samples.
@en
Generalizability of clinical t ...... disorder to community samples.
@nl
type
label
Generalizability of clinical t ...... disorder to community samples.
@en
Generalizability of clinical t ...... disorder to community samples.
@nl
prefLabel
Generalizability of clinical t ...... disorder to community samples.
@en
Generalizability of clinical t ...... disorder to community samples.
@nl
P2093
P2860
P356
P1476
Generalizability of clinical t ...... disorder to community samples.
@en
P2093
Caroline Dubertret
Nicolas Hoertel
Pierre Lavaud
Yann Le Strat
P2860
P304
P356
10.1002/DA.21937
P577
2012-04-11T00:00:00Z